MEOBF

Quote

Short

News

Articles

Message Board

Mesoblast Ltd (OTCMKTS : MEOBF ) News

Mesoblast Ltd (OTCMKTS: MEOBF) News Releases

MEOBF News Releases

April 29, 2026 08:55:01 pm

GlobeNewswire

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

April 28, 2026 08:53:16 pm

GlobeNewswire

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

April 14, 2026 08:10:56 pm

GlobeNewswire

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

April 10, 2026 04:09:52 pm

GlobeNewswire

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

April 09, 2026 01:56:11 am

SeekingAlpha

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

April 08, 2026 09:07:53 am

GlobeNewswire

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

April 07, 2026 11:35:17 pm

GlobeNewswire

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

April 06, 2026 09:03:58 pm

GlobeNewswire

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

March 17, 2026 07:19:57 pm

GlobeNewswire

Mesoblast to Host R&D Day on April 8, 2026

March 11, 2026 07:21:39 pm

GlobeNewswire

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account